Zheng Quan Shi Bao Wang·2026-01-04 03:57Group 1 - The core point of the news is that China Biologic Products (01177.HK) has seen significant insider buying from its executive director, demonstrating confidence in the company's long-term development [1] - Executive Vice President Xie Xin purchased 1 million shares at an average price of HKD 6.4068 per share, totaling approximately HKD 6.4068 million, increasing his holdings to 361 million shares, representing 1.92% of the company [1] - This marks Xie Xin's third purchase since July 2025, with previous purchases made at average prices of HKD 6.47 and HKD 7.36, indicating a total investment of over HKD 20 million in the past six months [1] Group 2 - The mid-year report for 2025 indicates that China Biologic Products' innovative transformation is showing significant results, with expectations that revenue from innovative products will exceed 50% of total revenue [2] - The company has achieved several milestones since December last year, including the approval of the breast cancer innovative drug Kemosil capsules, which is the world's first CDK2/4/6 inhibitor [2] - Other notable advancements include the clinical application approvals for the oral GLP-1 receptor agonist TQF3250 for weight loss by both the NMPA and FDA, and positive progress in the phase II clinical trial of the TYK2/JAK1 inhibitor TQH3906 for plaque psoriasis [2]